Zekri, J.; Mokhtar, M.; Karim, S.M.; Darwish, T.; Al-Foheidi, M.; Rizvi, A.; Al-Rehaily, S.; Mahrous, M.; Mansour, M.
(Experimental Oncology, 2015)
Background: Lapatinib alone or in combination with other agents, mostly capecitabine is used for patients with advanced/metastatic HER2 positive breast cancer (HER2+BC) after progression on trastuzumab based therapy. Here ...